Screener
Bicara Therapeutics BCAX Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Income tax expense | (52) | (72) |
| Net loss | $(56,211) | $(36,846) |
| Net Loss per share, basic and diluted | $(0.93) | $(0.68) |
| Weighted-average number common shares outstanding, basic and diluted | 60,717,041 | 54,456,515 |
| Other comprehensive loss: | ||
| Unrealized loss on marketable securities, net of tax | (486) | — |
| Total other comprehensive loss | (486) | — |
| Total comprehensive loss | $(56,697) | $(36,846) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's shares (diluted)?
- Bicara Therapeutics (BCAX) reported shares (diluted) of 60.7M in Q1 2026.
- How has Bicara Therapeutics's shares (diluted) changed year-over-year?
- Bicara Therapeutics's shares (diluted) increased by 11.5% year-over-year, from 54.5M to 60.7M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Bicara Therapeutics's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude